This webinar delves into the dynamic landscape of COAs, examining their historical use and significance, current uses and best practices, and making a case for greater standardization in their implementation.
Clinical outcomes assessments (COAs) have emerged as invaluable tools in health economics, offering a lens through which to assess the individual impact of medical interventions, patient experience, and beliefs of the patient. From oncology to mental health, they are revolutionizing patient-centered care, enabling more personalized treatments, and enhancing communication between healthcare providers and patients. However, they require special training and considerations to optimize these benefits and protect data integrity across sites in atrial setting.
Key Topics Include:
- Evolving industry attitudes and practices in COA administration
- COA applications across various clinical domains and their vital role in healthcare and health economics research
- The implications and potential of artificial intelligence (AI), ePRO, wearable devices, telemedicine, and other technology advancements regarding patient centricity
- Best practices and case studies that illustrate the importance of COA administration training and standardization
Resources
Presenters
Principal
Patient Centred Outcomes
ICON
Kelly Lipman acts as the Scientific Project Director for rater training within ICON's Patient-Centred Outcomes (PRO) team. Kelly has supported many PRO projects in a variety of capacities since her start with ICON in 2015.
Senior Outcomes Researcher
Patient Centred Outcomes
ICON
Heather Dickerson is a Senior Outcomes Researcher within ICON’s Patient Centred Outcomes (PCO) team and acts as the scientific research lead for rater training. Heather is an experienced qualitative researcher with expertise in clinical trial management, protocol development, COA (Clinical Outcome Assessment) validation and localization, qualitative interviewing, and COA training.
Senior Outcomes Researcher
Patient Centred Outcomes
ICON
Ryan Murphy is an Outcomes Researcher in the Patient Centred Outcomes (PCO) team within the ICON Insights, Evidence & Value group. Ryan joined ICON in 2016 as a qualitative researcher with a background in survey design and has gained expertise in the development and content validation of clinical outcomes assessments and qualitative interviewing.
Production Partner
ICON
Our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life.
Additional Content From ICON
Strategies to Optimize Commercialization of Oncology Treatments for Younger Adults
Watch this webinar on addressing early onset cancer through strategic trial design, targeted launch indications, and increased trial access to speed up the delivery of impactful treatments.
Minimizing the Impact of Cross-Cultural Differences in COA Translations
ICON's COA Linguistic Validation Leaders highlight the importance of Linguistic Validation and how equivalence should be a key focus during the development of Clinical Outcome Assessment translations.
Medicare Part D: Price Negotiation Panel Discussion
Hear expert panelists bring their perspectives on critical issues around support for Medicare Part D products' fair market prices.
Related Content
Patient Voices Matter: Transforming Industry-Sponsored Real-World Evidence with Patient-Centric Approaches
In this webinar, panelists address integrating patient-centered research into real-world studies, focusing on diversity, equity, and inclusion (DEI), and developing systemic approaches for a more equitable research ecosystem.
Cell & Gene Therapies – Beginning with the End in Mind
This webinar discusses how early stage planning taking into account commercial production, logistics, reimbursement, and health inequities can lead to successful approvals and market adoption.
Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases
Watch this webinar exploring real challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases to support clinical development through commercial post-approval.